Literature DB >> 12794243

Histopathological study of intraductal papillary mucinous tumor of the pancreas: special reference to the roles of Survivin and p53 in tumorigenesis of IPMT.

Ma Jinfeng1, Wataru Kimura, Fumiaki Sakurai, Toshiyuki Moriya, Akiko Takeshita, Ichiro Hirai.   

Abstract

AIM: In this study, we investigated the tissue expression of Survivin, p53, and Bcl-2 in intraductal papillary-mucinous tumor (IPMT) of the pancreas to identify their roles in tumorigenesis of IPMT, and examined their correlations with tumor cell apoptosis and proliferation in IPMT. The diagnostic values of the expression of Survivin, p53, and Bcl-2 and the apoptotic index (AI) and Ki-67 labeling index (Ki-67 LI) in IPMT were also examined.
METHODS: Twenty-two lesions from 17 patients with IPMT, including 12 benign (IPMT Adenoma) and 10 malignant (IPMT Carcinoma In Situ [CIS] (n = 4) and Invasive IPMT (n = 6) lesions, were immunostained for Survivin, p53, Bcl-2 and Ki-67. The apoptotic cells were detected by the Apop Tag(R) In Situ Oligo Ligation (ISOL) method.
RESULTS: The immunoreactivities for Survivin and p53 significantly increased in the transition from IPMT Adenoma to IPMT CIS (p < 0.05 for both). This transition was associated with a significant decrease in tumor cell apoptosis ( p < 0.001). The expression of Survivin was significantly associated with AI in IPMT ( p < 0.01), but not with Ki-67 LI. The expressions of Survivin and p53, and AI and Ki-67 LI were also significantly different between benign IPMT and malignant IPMT. Bcl-2 was not expressed in IPMT.
CONCLUSION: These results suggest that Survivin and p53 may play important roles in the transition from IPMT Adenoma to IPMT CIS. This transition is accompanied by a significant decrease in tumor cell apoptosis. Survivin is significantly associated with the change in AI in IPMT. The immunohistochemical detection of Survivin and p53 as well as the determination of the AI and Ki-67 LI have useful roles in the diagnosis of IPMT.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12794243     DOI: 10.1385/IJGC:32:2-3:73

Source DB:  PubMed          Journal:  Int J Gastrointest Cancer        ISSN: 1537-3649


  43 in total

1.  Anti-apoptosis gene, survivin, and prognosis of neuroblastoma.

Authors:  C Adida; D Berrebi; M Peuchmaur; M Reyes-Mugica; D C Altieri
Journal:  Lancet       Date:  1998-03-21       Impact factor: 79.321

2.  Pancreatic intraepithelial neoplasia: a new nomenclature and classification system for pancreatic duct lesions.

Authors:  R H Hruban; N V Adsay; J Albores-Saavedra; C Compton; E S Garrett; S N Goodman; S E Kern; D S Klimstra; G Klöppel; D S Longnecker; J Lüttges; G J Offerhaus
Journal:  Am J Surg Pathol       Date:  2001-05       Impact factor: 6.394

3.  Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma.

Authors:  A I Sarela; R C Macadam; S M Farmery; A F Markham; P J Guillou
Journal:  Gut       Date:  2000-05       Impact factor: 23.059

Review 4.  BCL-2, a novel regulator of apoptosis.

Authors:  J R Park; D M Hockenbery
Journal:  J Cell Biochem       Date:  1996-01       Impact factor: 4.429

5.  Intraductal papillary neoplasm of the pancreas.

Authors:  K Nishihara; T Fukuda; M Tsuneyoshi; T Kominami; S Maeda; M Saku
Journal:  Cancer       Date:  1993-08-01       Impact factor: 6.860

6.  Characteristics and treatment of mucin-producing tumor of the pancreas.

Authors:  W Kimura; M Makuuchi; A Kuroda
Journal:  Hepatogastroenterology       Date:  1998 Nov-Dec

7.  Infrequent stromal expression of gelatinase A and intact basement membrane in intraductal neoplasms of the pancreas.

Authors:  K Satoh; H Ohtani; T Shimosegawa; M Koizumi; T Sawai; T Toyota
Journal:  Gastroenterology       Date:  1994-11       Impact factor: 22.682

8.  p53 immunostaining in the distinction between benign and malignant mesothelial proliferations using formalin-fixed paraffin sections.

Authors:  F G Mayall; H Goddard; A R Gibbs
Journal:  J Pathol       Date:  1992-12       Impact factor: 7.996

9.  Inverse correlation between the expression of bcl-2 and p53 proteins in primary gastric lymphoma.

Authors:  S Nakamura; K Akazawa; N Kinukawa; T Yao; M Tsuneyoshi
Journal:  Hum Pathol       Date:  1996-03       Impact factor: 3.466

10.  Apoptosis in breast carcinomas detected with monoclonal antibody to single-stranded DNA: relation to bcl-2 expression, hormone receptors, and lymph node metastases.

Authors:  O S Frankfurt; J A Robb; E V Sugarbaker; L Villa
Journal:  Clin Cancer Res       Date:  1997-03       Impact factor: 12.531

View more
  9 in total

1.  Expression of Survivin in pancreatic cancer and its correlation to expression of Bcl-2.

Authors:  Jian-Guo Qiao; Yu-Qing Zhang; Yu-Chun Yin; Zui Tan
Journal:  World J Gastroenterol       Date:  2004-09-15       Impact factor: 5.742

2.  High-throughput mutation profiling in intraductal papillary mucinous neoplasm (IPMN).

Authors:  Nir Lubezky; Menahem Ben-Haim; Sylvia Marmor; Eli Brazowsky; Gideon Rechavi; Joseph M Klausner; Yoram Cohen
Journal:  J Gastrointest Surg       Date:  2011-01-12       Impact factor: 3.452

3.  Survivin and pancreatic cancer.

Authors:  Bin-Bin Liu; Wei-Hong Wang
Journal:  World J Clin Oncol       Date:  2011-03-10

4.  Biological similarities and differences between pancreatic intraepithelial neoplasias and intraductal papillary mucinous neoplasms.

Authors:  Toshiyuki Moriya; Wataru Kimura; Shuho Semba; Fumiaki Sakurai; Ichiro Hirai; Jinfeng Ma; Akira Fuse; Kunihiko Maeda; Mitsunori Yamakawa
Journal:  Int J Gastrointest Cancer       Date:  2005

5.  Genetic markers of malignant transformation in intraductal papillary mucinous neoplasm of the pancreas: a meta-analysis.

Authors:  Sahar Nissim; Gregory E Idos; Bechien Wu
Journal:  Pancreas       Date:  2012-11       Impact factor: 3.327

6.  The role of apoptosis in blepharoptosis.

Authors:  E Şahlı; B M Hoşal; G Zilelioğlu; N Dinçer; G G Tezel
Journal:  Eye (Lond)       Date:  2013-04-19       Impact factor: 3.775

7.  Repurposing metformin, simvastatin and digoxin as a combination for targeted therapy for pancreatic ductal adenocarcinoma.

Authors:  Shi-He Liu; Juehua Yu; Justin F Creeden; Jeffrey M Sutton; Stephen Markowiak; Robbi Sanchez; John Nemunaitis; Andrea Kalinoski; Jian-Ting Zhang; Robert Damoiseaux; Paul Erhardt; F Charles Brunicardi
Journal:  Cancer Lett       Date:  2020-08-21       Impact factor: 8.679

8.  Nuclear survivin expression is a positive prognostic factor in taxane-platinum-treated ovarian cancer patients.

Authors:  Anna Felisiak-Golabek; Alina Rembiszewska; Iwona K Rzepecka; Lukasz Szafron; Radoslaw Madry; Magdalena Murawska; Tomasz Napiorkowski; Piotr Sobiczewski; Beata Osuch; Jolanta Kupryjanczyk
Journal:  J Ovarian Res       Date:  2011-11-10       Impact factor: 4.234

9.  Survivin expression and its clinical significance in pancreatic cancer.

Authors:  Myung Ah Lee; Gyeong-sin Park; Hee-Jung Lee; Ji-Han Jung; Jin-Hyoung Kang; Young Seon Hong; Kyung Shik Lee; Dong-gu Kim; Seung-Nam Kim
Journal:  BMC Cancer       Date:  2005-10-04       Impact factor: 4.430

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.